Posted: Jan 21, 2020 5:32 am
Walked into a walkin clinic and fell down the rabbit hole.
Doc didn't like what he felt.
Songram and blood work same day and urologist the next day. He liked even less and surgery the next Tuesday. 6 months of the whole meal deal ( my oncologist has a sense of humour ) chemo, spinal chemo and radiation and no more lymphoma,
He said you might be back to see me for cancer but it won't be this one.
This was the big jump in survival rate
http://chemocare.com/chemotherapy/drug- ... ximab.aspx
Take away...you feel a bump ...get it checked. ( it's what the doc is looking for when he checks you lymph nodes )
Too bad breast cancer has not seen the progress but maybe the approach above will provide some.
Ontario medical system can perform very well in acute circumstances.
Doc didn't like what he felt.
Songram and blood work same day and urologist the next day. He liked even less and surgery the next Tuesday. 6 months of the whole meal deal ( my oncologist has a sense of humour ) chemo, spinal chemo and radiation and no more lymphoma,
He said you might be back to see me for cancer but it won't be this one.
This was the big jump in survival rate
How Rituximab Works:
Rituximab is classified as a monoclonal antibody. Monoclonal antibodies are a relatively new type of "targeted" cancer therapy.
Antibodies are an integral part of the body's immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a germ) that has entered the body. The antibodies attach to the antigen in order to mark it for destruction by the immune system.
To make anti-cancer monoclonal antibodies in the laboratory, scientists analyze specific antigens on the surface of cancer cells (the targets). Then, using animal and human proteins, they create a specific antibody that will attach to the target antigen on the cancer cells. When given to the patient, these monoclonal antibodies will attach to matching antigens like a key fits a lock.
Since monoclonal antibodies target only specific cells, they may cause less toxicity to healthy cells. Monoclonal antibody therapy is usually given only for cancers in which antigens (and the respective antibodies) have been identified already.
Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment.
http://chemocare.com/chemotherapy/drug- ... ximab.aspx
Take away...you feel a bump ...get it checked. ( it's what the doc is looking for when he checks you lymph nodes )
Too bad breast cancer has not seen the progress but maybe the approach above will provide some.
Ontario medical system can perform very well in acute circumstances.